Skip to Content
You are currently on the new version of our website. Access the old version .
BiomoleculesBiomolecules
  • Review
  • Open Access

2 March 2023

26 Pages

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy

,
,
and
Department of Gynecology, The Second Hospital of Jilin University, Changchun 130000, China
*
Authors to whom correspondence should be addressed.
This article belongs to the Section Molecular Biology

Abstract

Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.